STAT reports that the FDA has provided new details on an accelerated approval pathway for personalised gene therapies. Rare disease advocates praised the announcement, suggesting it could improve access to treatments for patients with limited options.
This update matters for pharma and biotech leaders, as regulatory changes may affect the speed and cost of bringing new therapies to market. Companies should monitor further guidance from the FDA and assess how these changes could influence development strategies.
